drugset / Trial / NCT05517902

StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

NCT05517902 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Autografting is a surgical procedure to transplant healthy skin (donor skin) from another part of the participant's own body (donor site) to the burned part. Autografting is the usual treatment for DPT burns. It works to close the wound, but can cause other problems: * Donor sites are painful, can become infected or scarred, or can even become full thickness (FT) wounds themselves * Treatment problems can require more grafting * Additional surgery increases the risk of medical problems caused by the treatment Stratatech is trying to find a safe and effective alternative to autografting to promote the healing of severe burns. The purpose of this study was to evaluate whether StrataGraft treatment eliminates or reduces the need for autografting and promotes wound closure in a pediatric population with thermal burns that contain intact dermal elements and for which autografting is clinically indicated (DPT burns). Participants were enrolled into one of two age-based cohorts: 2 to \< 12 years and 12 to ≤ 17 years to receive a single application of StrataGraft, in up to 3 non-contiguous DPT burn areas located on the same extremity or plane of the torso.

Timeline

Start
2023-04-28
Primary completion
2024-05-09
Completion
2024-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject StrataGraft Other / unclassified — —

Indications

No indication recorded.